1,470 Shares in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Bought by Meiji Yasuda Asset Management Co Ltd.

Meiji Yasuda Asset Management Co Ltd. purchased a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 1,470 shares of the biopharmaceutical company’s stock, valued at approximately $218,000.

A number of other institutional investors have also made changes to their positions in the stock. US Bancorp DE boosted its position in Alnylam Pharmaceuticals by 6.8% during the 2nd quarter. US Bancorp DE now owns 1,115 shares of the biopharmaceutical company’s stock worth $165,000 after purchasing an additional 71 shares during the period. World Asset Management Inc boosted its position in Alnylam Pharmaceuticals by 3.8% during the 2nd quarter. World Asset Management Inc now owns 2,059 shares of the biopharmaceutical company’s stock worth $305,000 after purchasing an additional 75 shares during the period. D.A. Davidson & CO. boosted its position in Alnylam Pharmaceuticals by 4.0% in the 2nd quarter. D.A. Davidson & CO. now owns 2,009 shares of the biopharmaceutical company’s stock valued at $298,000 after buying an additional 78 shares during the last quarter. Commonwealth Equity Services LLC boosted its position in Alnylam Pharmaceuticals by 2.0% in the 2nd quarter. Commonwealth Equity Services LLC now owns 4,214 shares of the biopharmaceutical company’s stock valued at $624,000 after buying an additional 84 shares during the last quarter. Finally, Shell Asset Management Co. boosted its position in Alnylam Pharmaceuticals by 2.3% in the 1st quarter. Shell Asset Management Co. now owns 4,504 shares of the biopharmaceutical company’s stock valued at $490,000 after buying an additional 100 shares during the last quarter. 96.04% of the stock is owned by hedge funds and other institutional investors.

In related news, EVP Laurie Keating sold 47,250 shares of the stock in a transaction dated Monday, July 13th. The shares were sold at an average price of $160.67, for a total transaction of $7,591,657.50. Following the sale, the executive vice president now owns 16,433 shares in the company, valued at $2,640,290.11. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO John Maraganore sold 34,765 shares of the stock in a transaction dated Thursday, August 20th. The stock was sold at an average price of $136.13, for a total transaction of $4,732,559.45. In the last quarter, insiders have sold 115,516 shares of company stock worth $17,695,390. 3.50% of the stock is owned by company insiders.

A number of research firms have weighed in on ALNY. ValuEngine raised shares of Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Monday, August 3rd. HC Wainwright reissued a “buy” rating on shares of Alnylam Pharmaceuticals in a research report on Monday, August 24th. Chardan Capital reissued a “buy” rating on shares of Alnylam Pharmaceuticals in a research report on Friday, August 7th. BMO Capital Markets upped their price objective on shares of Alnylam Pharmaceuticals from $173.00 to $196.00 and gave the company an “outperform” rating in a research report on Monday, July 20th. Finally, BidaskClub lowered shares of Alnylam Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating and fourteen have given a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $149.95.

ALNY opened at $122.83 on Friday. The firm has a market cap of $14.52 billion, a price-to-earnings ratio of -16.23 and a beta of 1.63. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $73.32 and a fifty-two week high of $167.33. The company’s 50-day moving average price is $144.31 and its 200 day moving average price is $133.19. The company has a quick ratio of 5.42, a current ratio of 5.62 and a debt-to-equity ratio of 0.20.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($1.56) earnings per share for the quarter, topping the consensus estimate of ($1.82) by $0.26. The firm had revenue of $77.50 million for the quarter, compared to analyst estimates of $98.76 million. Alnylam Pharmaceuticals had a negative net margin of 245.14% and a negative return on equity of 58.40%. Alnylam Pharmaceuticals’s quarterly revenue was up 102.9% on a year-over-year basis. During the same quarter in the prior year, the business earned ($1.83) earnings per share. Research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -6.68 earnings per share for the current year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases.

Featured Article: How to Invest in Stocks with Increasing Dividends

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY).

Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.